Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)

NCT00783926 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

422

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza
Pandemic Influenza

Interventions

BIOLOGICAL: H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)

Sponsor

Alachua Government Services, Inc.